Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXLOW study: very low-dose oral immunotherapy for severe walnut allergy in children
jRCTs031260139Recruiting
- Sponsor
- Nipponham Foundation for the Future of Food
- Start
- Jun 2026
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial of standardized walnut antigen in Walnut allergy (3 arms), sponsored by Nipponham Foundation for the Future of Food. Primary endpoint: Trend of change in walnut antigen-specific IgG4 levels. Started Jun 2026; status: recruiting.
02
Drugs
standardized walnut antigen
03
Conditions
Walnut allergy
Beyond the preview
Go deeper on jRCTs031260139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260139.